Institution-Grade Tools, Priced for Individual Investors.
Receive trading alerts directly to your inbox. Try Barchart Plus or Barchart Premier for free today.
/AI%20(artificial%20intelligence)/AI%20Data%20Center%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
Nike stock is sinking as disappointing guidance and longer-than-expected turnaround timelines continue to hurt sentiment. Truist explains why now is a great time to load up on NKE shares.
/Apple%20Inc%20logo%20on%20Apple%20store-by%20PhillDanze%20via%20iStock.jpg)
Apple has kept up with the decades, starting with gaming products and Macs to iPods, iPhones, and smartwatches. So can the first U.S. company to hit $1 trillion continue on its famous expansion journey?...
Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.
/Boeing%20Co_%20plane-by%20Wirestock%20via%20iStock.jpg)
With regulatory overhangs easing, Boeing is returning to growth.
/Unitedhealth%20Group%20Inc%20%20phone%20and%20site-by%20T_Schneider%20via%20Shutterstock.jpg)
Beaten-down UnitedHealth stock has received an “Outperform” rating from Raymond James analysts.
/A%20Tesla%20Cybertruck%20with%20visible%20bullet%20impacts_%20Image%20by%20Karolis%20Kavolelis%20via%20Shutterstock_.jpg)
Tesla stock sinks on disappointing Q1 deliveries. But Dan Ives continues to recommend sticking with TSLA shares in 2026.
Gold has corrected from the late January all-time high. The leading precious metal is trading over $1,000 below the all-time peak, and remains under pressure despite geopolitical events.
A technical breakout call is putting ADM back in focus, with one strategist seeing upside despite ongoing fundamental pressures.
Sky Quarry stock soars as Trump warns the U.S. could hit Iran very hard in April. Here’s why SKYQ shares may be worth owning at current levels.
/Super%20Micro%20Computer%20Inc%20logo%20on%20building-by%20Poetra_RH%20via%20Shutterstock.jpg)
Legal scrutiny is clouding Super Micro’s strong AI-driven growth, prompting investors to rethink its credibility as the trial timeline tightens.
